UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 118,991 Shares of Avantor, Inc. $AVTR

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Avantor, Inc. (NYSE:AVTR) by 5.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,027,738 shares of the company’s stock after selling 118,991 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Avantor were worth $20,075,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AVTR. Private Management Group Inc. grew its position in Avantor by 50.4% during the 4th quarter. Private Management Group Inc. now owns 2,456,859 shares of the company’s stock worth $28,156,000 after acquiring an additional 823,572 shares during the last quarter. GSA Capital Partners LLP bought a new position in Avantor in the 2nd quarter valued at $800,000. Oppenheimer Asset Management Inc. bought a new position in Avantor in the 2nd quarter valued at $805,000. Assenagon Asset Management S.A. boosted its stake in Avantor by 425.0% in the second quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock worth $5,513,000 after purchasing an additional 450,801 shares in the last quarter. Finally, Brickwood Asset Management LLP boosted its stake in Avantor by 6,891.9% in the fourth quarter. Brickwood Asset Management LLP now owns 3,184,043 shares of the company’s stock worth $36,489,000 after purchasing an additional 3,138,504 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Stock Down 1.5%

Shares of NYSE AVTR opened at $14.96 on Friday. Avantor, Inc. has a 1 year low of $7.26 and a 1 year high of $15.93. The firm’s 50-day moving average is $12.62 and its 200-day moving average is $9.93. The company has a current ratio of 1.78, a quick ratio of 1.18 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $10.12 billion, a PE ratio of -17.81, a price-to-earnings-growth ratio of 11.46 and a beta of 0.89.

Avantor (NYSE:AVTR) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. During the same period last year, the firm earned $0.24 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities analysts expect that Avantor, Inc. will post 0.81 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AVTR. UBS Group set a $8.00 price target on Avantor in a report on Wednesday, June 24th. TD Cowen restated a “hold” rating on shares of Avantor in a research report on Wednesday, July 15th. Stifel Nicolaus upped their target price on shares of Avantor from $8.00 to $15.00 and gave the stock a “hold” rating in a research report on Thursday, July 30th. Barclays increased their price target on shares of Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Finally, Morgan Stanley boosted their price objective on shares of Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.00.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.